Cannabix Technologies Develops Beta 2.0 Marijuana Breathalyzer
VANCOUVER, BRITISH COLUMBIA -- 10/19/16 Cannabix Technologies Inc. (CSE:BLO)(CSE:BLO.CN)(OTC PINK:BLOZF) (the "Company") provides an update on the development of its FAIMS (high-field asymmetric waveform ion mobility spectrometry) based instrument for detection of trace amounts of tetrahydrocannabinol ("THC") from exhaled breath at the roadside and in the workplace. The Company is pleased to report that it has developed a "Beta 2.0" (Cannabix Marijuana Breathalyzer) device with major advances in the design and size of the device, including: greater sensitivity, improved performance by the square waveform generator. The current design includes features to allow for the addition of a rechargeable battery and touch screen and the device is approximately 10 times smaller than the Beta 1.0 device announced in July. Preliminary lab tests of the FAIMS device coupled with quadrupole ion trap mass spectrometry have shown lower levels of detection for THC standards than were achieved in past testing.
Scientific Testing for the FAIMS Cannabix Marijuana Breathalyzer
Cannabix scientists are formulating a scientific protocol to conduct live THC breath testing using the Beta 2.0 Cannabix Marijuana Breathalyzer in the coming weeks. The scientific testing will likely be conducted in Vancouver BC, Canada, where medical marijuana users will be engaged to determine the accuracy of the Beta 2.0 Cannabix Marijuana Breathalyzer to detect both smoked and edible consumption of marijuana in human breath. The results of the scientific tests will be used to prepare submissions for approval of the Cannabix Marijuana Breathalyzer as a court-approved device by the Minister of Justice in Canada and the National Highway and Safety Authority in the United States.